The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Stork
Advised Arle Capital Partners on the sale of Stork, an international provider of maintenance, modification and asset integrity services for large existing industrial facilities in the oil and gas, chemicals, industrial and power markets, to Fluor Corporation, one of the world’s largest publicly-traded engineering, procurement and construction companies
Aesynt, Inc.
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
Willbros Professional Services
Advised Willbros Group, Inc. on the sale of its Professional Services segment to TRC Companies, Inc.
International Medical Group, Inc.
Advised International Medical Group, Inc., a leader in the global insurance and assistance services market, on its sale to ABRY Partners
COOEC Fluor Heavy Industries Co., Ltd.
Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
Altegra Health, Inc.
Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare
28-property portfolio of independent living senior housing properties from affiliates of Holiday Retirement, an entity controlled by Fortress Investment Group
Provided Fairness Opinion to the Transaction Committee of the Board of Directors of New Senior Investment Group, a $2.5 billion publicly traded REIT, on its acquisition of a 28-property portfolio from Holiday Retirement, one of the largest private operators of senior housing in the US
Niska Gas Storage Partners
Advised the Conflicts Committee of the Board of Directors of Niska and provided a fairness opinion on its sale to Brookfield
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
Telecity Group plc
Advised Telecity Group plc, Europe’s leading provider of premium carrier-neutral data centres, on a recommended cash and share offer from Equinix, Inc. a leading US provider of colocation data centre services globally
Nordstrom, Inc. (Credit Card Assets)
Advised The Toronto-Dominion Bank Group on its acquisition of Nordstrom, Inc.’s credit card assets
Tate & Lyle plc
Advised Tate & Lyle plc, a leading provider of ingredients and solutions to the food, beverage and other industries, on the re-alignment of Eaststarch C.V., its 50:50 corn wet milling joint venture in Europe with Archer Daniels Midland Company
Lion's Everyday Cheese Business
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Everyday Cheese business to Warrnambool Cheese & Butter, a listed Australian dairy company controlled by the Canadian dairy player Saputo
Softcard (JVL Ventures, LLC)
Advised Softcard, a joint venture of AT&T, Verizon and T-Mobile focused on mobile payments and commerce, on the sale of certain assets to Google
GFI Group Inc.
Advised the Special Committee of GFI Group Inc. on its sale to BGC Partners, Inc.
Hiland Partners, LP
Advised Hiland Partners, a leading midstream energy company with operations primarily in the Bakken Shale, on its sale to Kinder Morgan, North America’s largest energy infrastructure company
NYK Ports LLC
Advised NYK Ports LLC, a leading port operating and stevedoring company, on the sale of a 49% stake to Macquarie Infrastructure Partners, a leading Australian infrastructure fund
Tipness Limited
Advised Nippon Television Holdings, a media and content company engaged in production and broadcasting primarily in Japan, on the acquisition of Tipness Limited, the fourth largest fitness club company in Japan, from Suntory Holdings and Marubeni Corporation
Voya Financial, Inc.
Advised the Independent Committee of the Board of Directors of Voya Financial, Inc. in connection with Voya Financial, Inc.’s repurchase of 4.5mm shares (aggregate repurchase of $175mm) from ING Groep N.V.
Masco Corporation
Advised Masco Corporation, a leading global provider of home improvement and building products, on the tax-free spin-off of its Installation Services business
Voya Financial, Inc.
Advised the Independent Committee of the Board of Directors of Voya Financial, Inc. in connection with Voya Financial, Inc.’s repurchase of 7.7mm shares (aggregate repurchase of $300mm) from ING Groep N.V.
MannKind Corporation
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
Siemens Health Services
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
Clinuvel Pharmaceuticals Limited
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases